TPST
NASDAQTempest Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.25-0.02 (-1.18%)
03:30 PM05:00 PM
News · 26 weeks55+43%
2025-12-142026-06-07
Mix3590d
- SEC Filings21(60%)
- Other5(14%)
- Insider5(14%)
- Leadership3(9%)
- Offering1(3%)
Latest news
25 items- INSIDERNew insider Richey William Drake claimed ownership of 2,000 shares (SEC Form 3)3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- INSIDERSEC Form 4 filed by Director Richey William Drake4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- SECSEC Form DEF 14A filed by Tempest Therapeutics Inc.DEF 14A - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of DirectorsBRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or "Tempest Therapeutics") today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the "Board"), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board. "Over the past several months, we have built a portfolio of CAR-T cell therapy product candidates targeting safe, effective treatments for patients with advanced cancers," said Matt Angel, Ph.D., President and CEO of Tempest. "The addition of Drake and John to the Boa
- SECSEC Form PRE 14A filed by Tempest Therapeutics Inc.PRE 14A - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross ProceedsBRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) (the "Company"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the entry a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 1,172,414 shares of the Company's common stock originally issued by the Company on November 26, 2025, having an original exercise price of $3.50 per share, at a reduced exercise price of $1.73 per share. The closing of the warrant exercise transaction is expected to occur on or about May 29, 2025, subject to satisfaction of
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form 10-Q filed by Tempest Therapeutics Inc.10-Q - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Reports First Quarter 2026 Financial Results and Provides Business UpdateAnnounced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children's Applied Gene and Cell Therapy Center ("AGCTC") as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of Business Development BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "We made strong progress in the first
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Presents Clinical Update at ISCT 2026 Annual Meeting100% complete response ("CR") rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials (REDEEM-1 and POEMS-1)Favorable safety profile with no Grade >3 CRS or ICANS in REDEEM-1 trial evaluating TPST-2003 in relapsed/refractory multiple myeloma ("rrMM")100% CR as measured by normalization of serum vascular endothelial growth factor levels ("CRVEGF") rate among all five efficacy evaluable patients in POEMS-1 trial evaluating TPST-2003 in the rare disease, POEMS syndrome44 patients treated to date across three studiesResults support clinical benefit of parallel-structure dual-targeting CAR architecture in pa
- PRTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingPresentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myelomaData further support potential of TPST-2003 to improve outcomes for patients with extramedullary disease BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest") will present its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell ("CAR-T") therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (
- PRTempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-TDelivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal developmentTech transfer on track to support initiation of potentially registrational study in Q4 2026Key manufacturing milestone follows Tempest's recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% complete response in all six efficacy evaluable patients, and accelerated development timeline BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced C
- PRTempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing EffortsAdds dedicated business development leadership to support Tempest's strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D., as Head of Business Development. Dr. Fang will lead Tempest's global business development efforts, including strategic partners
- SECSEC Form 424B3 filed by Tempest Therapeutics Inc.424B3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form 424B3 filed by Tempest Therapeutics Inc.424B3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form EFFECT filed by Tempest Therapeutics Inc.EFFECT - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form EFFECT filed by Tempest Therapeutics Inc.EFFECT - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form D filed by Tempest Therapeutics Inc.D - Tempest Therapeutics, Inc. (0001544227) (Filer)
- INSIDERSEC Form 4 filed by Trojanowski Justin4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- INSIDERSEC Form 4 filed by Maestas Nicholas4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
TPST FAQ
6 questionsWhat does Tempest Therapeutics Inc. do?
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.Where does TPST stock trade?
Tempest Therapeutics Inc. (TPST) is listed on NASDAQ.What sector and industry is TPST in?
Tempest Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TPST?
Tempest Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1100.00 price target on 2026-01-22. Recent price targets range from $1100.00 to $1500.00.What companies are similar to TPST?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TPST side-by-side with any of them on Quantisnow.How can I track TPST on Quantisnow?
Quantisnow aggregates Tempest Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TPST to receive live email and push alerts on every new disclosure.